? Proteomics (PROT) Shared Resource The UNC Proteomics (PROT) Shared Resource (SR) provides state-of-the-art mass spectrometry-based qualitative and quantitative protein analyses for LCCC members. The PROT SR offers a variety of services to cancer researchers including: guidance in experimental design; protein and peptide identification; relative and absolute protein quantitation; analysis of protein modifications; activity-based proteomics; instrument training; and proteomic informatics. In addition to these basic proteomic services there are four cancer proteomic research themes, each involving active collaborations with LCCC investigators, which have been developed since the last renewal. These themes provide state-of-the art proteomic research technologies to members of the Cancer Center and include: i) chemical proteomics methods to interrogate the dynamic activation state of the cancer kinome; ii) quantifying both the proteome and phosphoproteome of patient tumors as part of the NCI CPTAC initiative; iii) mass spectrometry and computational methods for defining protein-protein interaction networks in cancer, including quantitative measurement of network dynamics; and iv) absolute quantification of proteins in complex protein mixtures by selective reaction monitoring (SRMs). The PROT SR is led by Lee Graves (MT), Professor of Pharmacology and director, and David Smalley, Facility Director. Three additional faculty are directly involved with the efforts of the PROT SR: Gary Johnson (MT), Kenan Distinguished Professor and Chair of the Department of Pharmacology and co-director of the Molecular Therapeutics Program, Ben Major (CCB), Associate Professor of Cell Biology & Physiology, and Xian Chen (IM), Professor of Biochemistry & Biophysics and technology director of the PROT SR. Together they provide strong synergistic leadership in mass spectrometry based proteomics with a proven record of productive collaboration with investigators in the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-42
Application #
9391965
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications